toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author Nielsen, K.G.; Bisgaard, H. url  doi
  Title The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children Type Journal Article
  Year (down) 2000 Publication American Journal of Respiratory and Critical Care Medicine Abbreviated Journal Am J Respir Crit Care Med  
  Volume 162 Issue 4 Pt 1 Pages 1500-1506  
  Keywords Administration, Inhalation; Airway Resistance/*drug effects; Asthma/diagnosis/*drug therapy; *Bronchial Provocation Tests; Budesonide/*administration & dosage; Child, Preschool; Cold Temperature; Double-Blind Method; Female; Humans; Male; Methacholine Chloride  
  Abstract We hypothesized that measurement of lung function (LF) and bronchial hyperresponsiveness (BHR) could serve as supplemental tools in evaluating the efficacy of treatment with inhaled corticosteroids in asthmatic children aged 2 to 5 yr. We studied 38 children (mean age: 53 mo; range: 35 to 71 mo) with moderately severe asthma in a single-center, randomized, double-blind, parallel-group, placebo-controlled study involving 8 wk of treatment. Budesonide (BUD) 400 microgram twice daily was administered via a pressurized metered-dose inhaler and metal spacer device. Symptom scores (SSc) and use of short-acting beta(2)-agonist were monitored with diary cards. LF in awake children was measured as the specific airway resistance (sRaw), using whole-body plethysmography; as resistance by the interrupter technique (Rint); and as resistance and reactance at 5 Hz (Rrs5, Xrs5) by the impulse oscillation technique. Cold air challenge (CACh) and methacholine challenge (MCh) were used to assess BHR. Children in the BUD group experienced significantly fewer night- and daytime symptoms (p < 0.05) and more symptom-free days (p < 0.05), but not nights (p = 0.07), than children in the placebo group. Daytime (p < 0.05) but not nighttime (p = 0.09) use of rescue medication and asthma exacerbation rates (3.7 versus 9.3 exacerbations/yr) (p = 0.006) were both in favor of BUD. LF measured with the Rint technique, Rrs5, and Xrs5 were significantly improved by BUD. BHR as measured by CACh improved significantly with BUD, whereas no improvement was found on MCh. In conclusion, inhaled BUD at a total dose of 800 microgram daily significantly improved SSc, asthma exacerbation rates, lung function, and BHR as assessed by CACh in asthmatic children aged 2 to 5 yr.  
  Address Department of Pediatrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark  
  Corporate Author Thesis  
  Impact Factor 12,996 First Author Nielsen, K.G. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Bisgaard, H.  
  ISSN 1073-449X ISBN Medium  
  Area Expedition Conference  
  Notes PMID:11029368 Approved no  
  Call Number Serial 225  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: